NewsEvents

Your Yourlocation: Home > Effects of tiotropium bromide(136310-93-5) combined with capsule on anti-inflammatory effects in patients with chronic obstructive pulmonary disease

To investigate the value of tiotropium bromide(136310-93-5) and noninvasive ventilation (NPPV) in patients with chronic obstructive pulmonary disease (COPD) complicated with respiratory failure (RF). Methods: From October 2013 to October 2015, 60 patients with COPD complicated with RF were randomly divided into two groups, 30 patients in each group. The control group received basic treatment plus NPPV, the observation group was given on the basis of the control group, the course of treatment were 12 weeks before and after treatment (FEV1), forced vital capacity (FVC) and FEV 1 /FVC; blood gas analysis indicators: arterial oxygen pressure (PaO2), arterial carbon dioxide partial pressure (PaCO2) and pH value (P <0.05). Results: After treatment, the levels of FEV1, FVC, FEV1 /FVC and PaO2 were significantly higher than those before treatment (P <0.05), PaCO2 was significantly decreased (P <0.05), and the improvement was significant (P <0.05). Conclusion: The combination of NPPV can improve the lung function and arterial blood gas of patients with COPD complicated with RF, which is helpful to the rehabilitation of patients.

To investigate the effect of tiotropium bromide(136310-93-5) adjuvant therapy on oxygenation and inflammatory response in patients with chronic obstructive pulmonary disease (COPD) complicated with type Ⅱ respiratory failure. Methods: A total of 58 patients with COPD complicated with type Ⅱ respiratory failure were enrolled in our hospital in August 2012, and were divided into observation group (n = 29) and control group (n = 29) according to single blind randomized control. The control group received clinical routine treatment, the observation group in the conventional treatment based on the addition of tiotropium bromide(136310-93-5) ammonium adjuvant therapy. Before and 30 days after treatment, pulmonary function was measured by lung function instrument. Oxygenation function was measured by blood gas analyzer. Serum inflammatory cytokines were measured by enzyme-linked immunosorbent assay (ELISA). Results: Before treatment, there were no significant differences in pulmonary ventilation function, oxygenation function and serum inflammatory cytokines between the two groups (P> 0.05). After treatment for 30 days, the first expiratory volume (FEV1), 75% vital capacity (FEF7 5%), peak expiratory flow rate (PEF), oxygenation index (PaO2 / FiO2), oxygen transport (IL-1β), interleukin-18 (IL-1β) and interleukin-18 (IL-1β) were significantly higher than those in the control group (P <0.05) 18), interleukin-27 (IL-27) and C-reactive protein (CRP) were significantly lower than those in the control group(P <0.05). Conclusion: Trastropium bromide adjuvant therapy can optimize the pulmonary ventilation and oxygenation function of COPD patients with type Ⅱ respiratory failure and reduce the degree of systemic inflammatory response.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved